NCT00593255View on ClinicalTrials.gov

Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
Interventions
DRUG

soluble human insulin

DRUG

insulin aspart

DRUG

insulin NPH

Trial Locations (5)

100034

Novo Nordisk Investigational Site, Beijing

100101

Novo Nordisk Investigational Site, Beijing

100853

Novo Nordisk Investigational Site, Beijing

150001

Novo Nordisk Investigational Site, Harbin

200433

Novo Nordisk Investigational Site, Shanghai

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00593255 - Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes | Biotech Hunter | Biotech Hunter